Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 1, 2005, Pages 78-81

  Shulman, Nancy S ^a   Delgado, Jamael ^a   Bosch, Ronald J ^b   Winters, Mark A ^a   Johnston, Elizabeth ^a   Shafer, Robert W ^a   Katzenstein, David A ^a   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Drug resistance; Hypersusceptibility; Nonnucleoside reverse transcriptase inhibitor; Reverse transcriptase; Susceptibility testing

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SUBSTITUTION; CODON; DRUG HYPERSENSITIVITY; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 18144387934     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000159517.78100.7b     Document Type: Article

References (22)

1. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem. 1991;266: 14670-14674.
2. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999-5008.
3. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
4. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
6. Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study. A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data. Abstract LB-22. Paper presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco.
7. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
8. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2002;345:398-407.
9. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol. 1994; 75:951-957.
10. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992;36: 2664-2669.
11. Selmi B, Deval J, Alvarez K, et al. The Y181C substitution in 3′-azido-3′-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J Biol Chem. 2003; 278:40464-40472.
12. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to nonnucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41-F47.
13. Shulman NS, Bosch RJ, Mellors JW, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18:1781-1785.
14. Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS. 2001;15:1125-1132.
15. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16:F33-F40.
16. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169-180.
17. Katzenstein DA, Bosch RJ, Hellmann N, et al. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17:821-830.
18. Leigh Brown AJ, Frost SD, Good B, et al. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol. 2004; 78:2242-2246.
19. Moreno S, Casado JL, Perez-Elias MJ, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. AIDS. 2003;17:1413-1414.
20. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 1993;37:1095-1101.
21. Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother. 2001;45:2276-2279.
22. Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3′ azido-3′ deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 1998;37:15908-15917.